Upadacitinib for Giant Cell Arteritis with Large Vessel Involvement
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have giant cell arteritis (GCA) that is either newly diagnosed or has come back after treatment.
- You must have active inflammation in the large blood vessels (like the aorta) that is confirmed by imaging (CT, MRI or PET scan).
- You must have tried or be unable to use tocilizumab (a standard GCA treatment) due to side effects, lack of response, or medical reasons.
- You must not be pregnant or breastfeeding, and must have no serious infections like HIV, hepatitis B or C, or active tuberculosis.
- You must not have had cancer in the last 5 years, severe kidney or liver problems, or a history of blood clots or severe heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
This trial tests if a shorter course of the steroid prednisone, combined with tocilizumab, works as well as a longer course for giant cell arteritis. You must already be starting tocilizumab and taking at least 20 mg of prednisone daily.
This study tests whether bosentan, a medicine usually used for blood pressure in the lungs, can help control inflammation and symptoms in patients with giant cell arteritis (GCA). The goal is to see if it can reduce the need for steroids and improve quality of life.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.